Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed this Form 8-K on December 14, 2023, reporting an amendment to its existing loan and security agreement with Hercules Capital, Inc. and other lenders. The amendment creates additional debt capacity and modifies interest rates, maturity, covenants, and fees. No quarterly or annual operating results are reported in this filing.
Key Financial Terms and Metrics
- Term-loan capacity: Increased from $200.0 million to $300.0 million.
- Funding at closing: $40.0 million of Tranche 2 was funded on December 14, 2023.
- Additional availability: The agreement provides up to $160.0 million of currently undrawn commitments through five additional tranches, subject to milestones and other conditions.
- Cash interest: Reduced from 10.75% to a floating rate based on the greater of 9.85% or WSJ Prime plus 1.35%, capped at 10.35%. The rate may decline by 0.35% upon achievement of specified milestones.
- Payment-in-kind interest: Reduced from 3.35% to 2.15% per year.
- Maturity and amortization: The interest-only period and maturity date were extended from October 2026 to December 2027.
- Minimum cash covenant: Reduced to 20% of outstanding principal.
- Closing fee: $250,000, payable at closing.
- Existing warrant: The existing warrant agreement will not apply to future advances under the amended loan agreement.
Material Changes Versus the Prior Agreement
- Expanded aggregate borrowing capacity by $100.0 million.
- Added five future funding tranches: $50.0 million through March 15, 2024; $25.0 million through June 15, 2024; $25.0 million through December 15, 2024; $50.0 million through June 30, 2025; and $50.0 million through December 31, 2025.
- Tranches 5 and 6 require achievement of specified revenue milestones.
- Reduced both cash and payment-in-kind interest rates and extended the financing term.
- Relaxed the minimum cash covenant but added or revised revenue and financial-condition requirements.
Guidance, Outlook, Risks, and Unusual Items
Beginning September 30, 2024, the company must achieve trailing three-month net product revenue of at least the applicable threshold: 30% of agreed projected 2024 revenue during 2024, and thereafter 25% of projected revenue or $120.0 million, as specified in the amendment.
The revenue requirement may be waived if the company maintains qualifying minimum cash reserves or market capitalization exceeding $900.0 million. The cash-reserve test is based on outstanding term-loan principal and applies a 50% threshold before trailing three-month net product revenue reaches $35.0 million and a 35% threshold thereafter.
Failure to satisfy applicable milestones, revenue tests, cash requirements, or other loan conditions could limit access to undrawn tranches or result in default-related consequences. The filing does not provide revenue, profit, cash-flow, liquidity-balance, or margin figures for a comparable prior period.
Important Facts for Investors to Verify
- Whether the company draws the remaining tranches and satisfies all milestone conditions.
- The outstanding principal balance, cash position, and compliance with the 20% minimum-cash covenant.
- Progress toward the required revenue thresholds beginning September 30, 2024.
- The applicable floating cash-interest rate, rate-cap operation, and any milestone-based reductions.
- Prepayment fees, end-of-term fees, collateral terms, and other provisions in the complete amended loan agreement, which the filing states will be included with the company’s 2023 Form 10-K.